Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Anileridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 9/20 | 0.63 |
| ▸ | OPRK1 known ✓ | P41145 | 6/20 | 0.63 |
| ▸ | KCNA3 | P22001 | 3/20 | 0.69 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.63 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anileridine SCHEMBL26333 | 0.96 | KCNA3 (0.74) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| Anileridine SCHEMBL27722317 | 0.96 | KCNA3 (0.74) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| Anileridine SCHEMBL119086 | 0.95 | KCNA3 (0.72) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| Anileridine SCHEMBL7119028 | 0.95 | KCNA3 (0.72) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| Pheneridine SCHEMBL1922392 | 0.88 | KCNA3 (0.86) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| Anileridine SCHEMBL8741179 | 0.88 | KCNA3 (0.66) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| Phenoperidine SCHEMBL28832646 | 0.87 | KCNA3 (0.67) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL7313939 | 0.82 | KCNA3 (1.00) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL11712840 | 0.80 | OPRM1 (0.82) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL11601769 | 0.79 | OPRM1 (0.80) | KCNA3OPRM1OPRD1OPRK1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3509607-A1 | FORMULATION FOR PREVENTING OR TREATING DENTIN-ASSOCIATED SYMPTOMS OR DISEASES, AND METHOD USING THE SAME | Sancastle Worldwide Corporation (TW) | 2019-07-17 | — | — | EP | claimed |
| CN-108064157-A | Formulations for preventing or treating dentinal tubule associated symptoms or diseases and methods of use thereof | 圣凯瑟世界股份有限公司 | 2018-05-22 | — | — | CN | claimed |
| WO-2018046978-A1 | FORMULATION FOR PREVENTING OR TREATING DENTIN-ASSOCIATED SYMPTOMS OR DISEASES, AND METHOD USING THE SAME | SANCASTLE WORLDWIDE CORPORATION (TW) | 2018-03-15 | — | — | WO | claimed |
| US-20180064757-A1 | FORMULATION FOR PREVENTING OR TREATING DENTIN-ASSOCIATED SYMPTOMS OR DISEASES, AND METHOD USING THE SAME | SANCASTLE WORLDWIDE CORPORATION (TW) | 2018-03-08 | — | — | US | claimed |
| US-20240145031-A1 | Methods and devices for drug repositioning and drug repurposing as nuclear receptor modulators | Precision Medicine Lab (NL) | 2024-05-02 | — | — | US | disclosed |
| US-20230001128-A1 | AEROSOLIZATION SYSTEMS, METHODS, AND APPARATUSES | SHUSTER GARY STEPHEN (CA) | 2023-01-05 | — | — | US | disclosed |
| US-20210290771-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-09-23 | — | — | US | disclosed |
| US-11000597-B2 | Engineered receptor/ligand system for delivery of therapeutic agents | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-05-11 | — | — | US | disclosed |
| US-10722562-B2 | Combinatorial analysis and repair | IMMUDEX APS (DK) | 2020-07-28 | — | — | US | disclosed |
| US-10376649-B2 | Drug delivery device for delivery of two or more independently user selectable multiple doses of medicaments with user operable variable dose locking mechanisms | WOCKHARDT LIMITED (IN) | 2019-08-13 | — | — | US | disclosed |
| EP-3509607-A1 | FORMULATION FOR PREVENTING OR TREATING DENTIN-ASSOCIATED SYMPTOMS OR DISEASES, AND METHOD USING THE SAME | Sancastle Worldwide Corporation (TW) | 2019-07-17 | — | — | EP | disclosed |
| CN-108064157-A | Formulations for preventing or treating dentinal tubule associated symptoms or diseases and methods of use thereof | 圣凯瑟世界股份有限公司 | 2018-05-22 | — | — | CN | disclosed |
| US-20110028460-A1 | TOPICAL FORMULATION | FQUBED, INC. | 2011-02-03 | — | — | US | disclosed |
| WO-2010009735-A2 | COMBINATORIAL ANALYSIS AND REPAIR | DAKO DENMARK A/S (DK) | 2010-01-28 | — | — | WO | disclosed |
| US-20080319092-A1 | Transdermal Drug Delivery Formulation | NUVO RESEARCH INC. (CA) | 2008-12-25 | — | — | US | disclosed |
| EP-1909772-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | Nuvo Research Inc. (CA) | 2008-04-16 | — | — | EP | disclosed |
| US-20070269379-A1 | Penetration Enhancer Combinations for Transdermal Delivery | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2007-11-22 | — | — | US | disclosed |
| WO-2007016766-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | NUVO RESEARCH INC. (CA) | 2007-02-15 | — | — | WO | disclosed |
| WO-2005009510-A2 | PENETRATION ENHANCER COMBINATIONS FOR TRANSDERMAL DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20030069318-A1 | Salts of analgesic substances in oil, and methods of making and using the same | GUILFORD PHARMACEUTICALS, INC. | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028460-A1 | TOPICAL FORMULATION | SPTLC1, SPTSSB, SPTLC3 | OPRM1 1887/4885OPRK1 1186/4885KCNA3 2956/4885 |
| US-20030069318-A1 | Salts of analgesic substances in oil, and methods of making and using the same | OPRL1, OPRK1, ACHE | OPRM1 8/4885OPRK1 2/4885KCNA3 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.